Exhibit 99.5
Lavie Bio Introduction April 2021
2 This presentation contains "forward-looking statements" relating to future events, and Lavie Bio (the “Company”) and its parent, Evogene Ltd. (“Evogene”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws. Such forward-looking statements may be identified by the use of such words as “believe”, “expect”, “anticipate”, “should”, “planned”, “estimated”, “intend” and “potential” or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene’s and our technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors”. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. Forward looking statement
3 The forkinfluencesthe farm Consumer preferences drive change and impact how food is grown Healthierfood Sustainable environment Productive agriculture Bettervalue
4 Farmers around the world invest* $200B+ annually in ag inputs to protect and nurture their crops $135B Chemical Fertilizers $55B Crop protection chemicals $8B Ag-Biological * Company estimations
5 The Ag-Biologicals opportunityDriving healthier produce, sustainability and productive agriculture Driving cropproductivity Faster GTF(go to field) Fastest growingag. inputs segment Pesticides ~10-15 years | ~$250M Microbiome ~5-8 years | <$15M Time Cost 2015 2019E 2024E *Source: MarketsandMarkets, industry publications Wave 1 Wave 2 $3.2B $7.0B $13.4B New modesof actionProtect from resistance evolvementSafe Company estimations
6 The Ag-Biologicalsuntapped potential Crop Protection & Fertilizers Ag-Biologicals Today Sustainability + +++ Efficacy +++ ++ Consistency +++ + Commercial viability +++ + * Company estimates
7 Our Mission Improve food quality, sustainabilityand agriculture productivity through microbiome based ag-biologicals technology and products
8 Ag-Biologicals Today Sustainability + +++ +++ Efficacy +++ ++ +++ Consistency +++ + +++ Commercial viability +++ + +++ Next genAg-Biologicals Crop Protection & Fertilizers The Ag-BiologicalsOpportunity * Company estimates
9 The Microbiome: Billions of microbes matter! Integral toplant ecosystems Nature’s largest ‘function bank’ ‘Live Engine’producing in the field
10 Biology Driven Design platform The microbiome OS Enabled by MicroBoost AI and Taxon platforms Discovery Billions > Promising few Optimization Promising few > products Application Products > Yield protection Platform
11 Decoding the natural diversityof genetic functionality Limitless possibilities, designs and functions:Go as far as imagination takes you Nature's functionaldiversity ProprietaryFunction Hub Functionbased design
12 Holistic AI drivenplatform harnessing the power of genomics Unlocking the complexmicrobiome interactions: Amplifythe positive Eliminate the negative Retrievethe lost Diversity SystemModelling GenomicPrism FunctionHub Design Biology Driven Design platform Platform
13 Path to market Lavie BioProduct Direct model Non – consolidated segmentsCommercialization through channelsRevenues from sales Lavie Bio product& tech inside Indirect model ConsolidatedsegmentsCommercialization through partner’s channelsRevenues from R&D / Milestones and royalties Lavie Bio techinside Indirect model Precision Optimization of 3rd party’s productsShort time to marketRevenues from sales or R&D / Milestones and royalties
Product Program Product focus Application Target market* Potential expansion* Discovery Pre-Development Development Stage 1 Development Stage 2 Pre-Commercialization Product* Bio-Stimulants LAV 211, 212Bio-stimulants 1 Seed treatment, Spring WheatNorth America 25M ACRES wheat North America 500M ACRES 2022 LAV 213, 218Bio-stimulants 2 Seed treatmentCornNorth AmericaEurope 120M ACREScorn US, EU 180M ACRES >2025 Bio-Pesticides LAV 311, 312Fruit rots FoliarF&VEuropeNorth America <$200M grapes chemicals usage +$150MAdditional F&V 2024 LAV 321, 322Downey mildew FoliarF&VEuropeNorth America <$350M grapes chemicals usage +$150MAdditional F&V 2025 LAV 431, 432Seedling disease(Pythium) Seed Treatment,Corn, soy, F&VNorth AmericaEurope <$500M <$200M >2025 LAV 441, 442Bio-Insecticides Seed Treatment,Corn, foliar soyNorth AmericaEurope <$1.5B existing traits and chemicals market <$500M >2025 14 Product pipeline * Company estimations
15 Bio-stimulants driving yield advantage 1st focus market – Spring Wheat, 25M acres (ND, MT, West Canada) LAV 211 Up to 25% yield gain >$20 add value per acreBetter than ag-biologicals benchmarks tested LAV 211 Untreated Yield improvement Trial Expected 1st sales in 2022 * * * * * * * * *p values<0.05
16 Bio-fungicides againstBotrytis & fruit rots High value markets, expected 1st sales in 2024 Better than ag-biologicals and comparable to chemicals benchmarks tested LAV.211 NTC Chemicalctr LAV 312 LAV 312 Untreated Biologicalctr LAV.312 60% 40% 20% 0% A A B Different letters indicate significant differences between groups (p values<0.05)
17 Established ‘End to End’ capabilities Confidential
18 Strategic shareholders 28% 72%
19 We’ve gotthe right team to nurture it Management Team Board of directors Ido Dor | CEO Leadership experience of 20+ years in business development, sales and channel management Michael Ionesco| VP Research Innovative research leader with deep biotechnology, big data and informatics expertise Dorit Kriener | CFO 20+ years of experience in corporate finance, public and private fundraising, strategy and accounting management Amir Bercovitz| VP Development Extensive development and product expertise in the ag-biologicals field for 30+ years – led introductions of 5 commercials products James Presnail | COO Extensive development and product expertise in the ag-biologicals field for 30+ years – led introductions of 5 commercials products Ofer Haviv Chairman of the board Evogene CEO Kristian Bjorneboe Seasoned business development leader Frederic C. Beudot Global Portfolio Leader for Biologicals at Corteva Agriscience™ Trevor Thissen Senior agriculture executive, experienced in marketing, sales, and go-to-market
20 Milestone Roadmap LAV211 product precommercialization phaseCommercial teamand GTMAdvance LAV 311 / 312 product development First product launch for LAV211 ($sales)Product advancement in regulation process for LAV311 / LAV312Strategic and GTM collaborations Product portfolio expansion – product launches ($sales)Precision Optimization product – Pre-LaunchEstablished market channels 2021 2022 2023-2024
21 Market opportunity Lavie Bio is uniquely positioned to improve how food is grown, protected & consumed Farm Postharvest Consumer
Thank you!